Chikungunya vaccine (live, attenuated)

DB18701ApprovedInvestigationalVaccines

Chikungunya vaccine (live, attenuated) is a live, attenuated vaccine used for the prevention of disease caused by chikungunya virus. Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.

Mechanism: Intramuscular injection of live chikungunya virus (CHIKV) vaccine elicits CHIKV-specific immune responses.
Curator reviewed · 1 reference
Primary indication: Ixchiq (chikungunya vaccine, live) is indicated for the prevention of disease caused by chikungunya virus in patients ≥18 years of age who are at increased risk of exposure to chikungunya virus.Curator reviewed · 1 structured indication
First approval: Canada, 2024 · United States, 2024
Code names: VLA1553
Brand names: Ixchiq

Resolves to

Compound

UNII2RM4VT46R8

Clinical / RWD

RxNorm2673238

What you can answer from here — as of April 22, 2025

431Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

2Marketed productsAcross 2 countries and 2 labellers

5+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Chikungunya vaccine (live, attenuated), and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account